In a recent proposal, the Biden administration has put forth a plan to have Medicare and Medicaid cover obesity medications, a move that could potentially benefit millions of Americans. This proposal, if approved, would allow individuals who are not currently covered to access new obesity drugs such as Wegovy from Novo Nordisk and Zepbound from Eli Lilly. The new drugs have shown to improve health outcomes in various ways, but an existing legislation from two decades ago has prevented Medicare from covering drugs for weight loss.
This proposal seeks to bypass that restriction by specifying that the drugs would be covered to treat obesity as a disease and prevent its related conditions. Chiquita Brooks-LaSure, the administrator of the Centers for Medicare and Medicaid Services (C.M.S.), highlighted the growing medical consensus that obesity should be treated as a chronic health condition, emphasizing the importance of early intervention.
If this proposal is enacted, every state Medicaid program would be required to cover obesity drugs, a significant shift from the current situation where only a few states provide such coverage. The C.M.S. estimates that approximately 3.4 million more Medicare patients and four million Medicaid patients would become eligible for obesity drugs, resulting in substantial costs for the programs.
The move is seen as a potentially popular but costly decision that the incoming Trump administration would need to endorse for it to become official. The classification of obesity as a chronic health condition and the proposal to cover obesity medications under Medicare and Medicaid could have significant implications for healthcare access and treatment in the United States.